IL6 and coronary artery disorder: ,2) The Japan EPA lipid intervention study (JELIS) trial has reported the preventive effects of EPA on coronary heart disease (CHD), and EPA aids in reducing the levels of triglyceride in patients with hypercholesterolemia.3) Furthermore, PUFAs play an important role in resolving inflammation as results of reducing inflammation markers such as interleukin-6, tumor necrosis factor-alpha (TNF-α), and interleukin-1β.4) TNF-α relates to peripheral arterial restenosis, cardiovascular dysfunction, and cardiovascular events.5